CATHIE LIKES TU SIMPLE!
I don't think she likes Russian trucks!
Anavex initiated with a Buy at BTIG 06:42 AVXL BTIG analyst Yun Zhong initiated coverage of Anavex with a Buy rating and $35 price target. The company's lead product candidate ANAVEX 2-73 has demonstrated a strong safety profile and compelling efficacy in multiple indications including Alzheimer's disease, Parkinson's disease dementia, and Rett syndrome, the analyst tells investors in a research note. The positive clinical data provide strong proof-of-concept that ANAVEX 2-73 should have strong versatility in different CNS disorders and a higher probability of success in each indication than drug candidates that modulate single pathways, Zhong adds.
I don't think she likes Russian trucks!
Anavex initiated with a Buy at BTIG 06:42 AVXL BTIG analyst Yun Zhong initiated coverage of Anavex with a Buy rating and $35 price target. The company's lead product candidate ANAVEX 2-73 has demonstrated a strong safety profile and compelling efficacy in multiple indications including Alzheimer's disease, Parkinson's disease dementia, and Rett syndrome, the analyst tells investors in a research note. The positive clinical data provide strong proof-of-concept that ANAVEX 2-73 should have strong versatility in different CNS disorders and a higher probability of success in each indication than drug candidates that modulate single pathways, Zhong adds.